Annual report pursuant to Section 13 and 15(d)

Note 2 - Summary of Significant Accounting Policies

v3.19.1
Note 2 - Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Significant Accounting Policies [Text Block]
2.
Summary of Significant Accounting Policies
 
Financial Statement Presentation
 
The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
  
Use of Estimates
 
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not
readily apparent from other sources. Actual results
may
differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results. 
 
Changes in Accounting Policies
 
Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements.
 
Adoption of New Accounting Standard
 
On
January 
1,
2018,
the Company adopted Revenue from Contracts with Customers (Topic
606
), which created Accounting Standards Codification Topic
606
(“ASC
606”
), using the modified retrospective method applied to those contracts which were
not
completed as of
January 
1,
2018.
Results for reporting periods beginning after
January 
1,
2018
are presented under ASC
606,
while prior period amounts are
not
adjusted and continue to be reported in accordance with our historic accounting under Accounting Standards Codification Topic
605
 (“ASC
605”
).
 
Previously under ASC
605,
revenue from extended assurance warranties was deferred and recognized over the period of the warranty. Under ASC
606,
these warranties are
not
considered a separate performance obligation.  Accordingly, on the transition date, the Company recorded a net cumulative adjustment in accumulated deficit of
$177,000,
resulting from the release of
$195,000
for the amount of extended warranties previously recorded in noncurrent liabilities, offset by
$18,000
recorded in accrued liabilities for future costs associated with the assurance-type extended warranties.
 
The details for the impact of the adoption of ASC
606
are provided below:
 
   
Balance as of
December 31,
2017
   
Adjustment
Due to
Adoption of
ASC 606
   
Balance as of
January 1,
2018
 
                         
Consolidated Balance Sheet:
 
 
 
 
 
 
 
 
 
 
 
 
                         
Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
  $
4,605
    $
18
(1)
 
  $
4,623
 
Other noncurrent liabilities
  $
327
    $
(195
)
(2)
  $
132
 
                         
Equity
 
 
 
 
 
 
 
 
 
 
 
 
Accumulated deficit
  $
(105,581
)
  $
177
(3)
 
  $
(105,404
)
 
 
(
1
)
   
Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC
606.
 
(
2
)
   
Change relates to long-term deferred revenue related to the extended warranties
not
required to be recorded under ASC
606.
 
(
3
)
   
Change relates to cumulative effect adjustment upon adoption of ASC
606.
  
Cash and Cash Equivalents
 
The Company considers all highly liquid investments purchased with an original maturity of
three
months or less, at the time of purchase, to be cash equivalents. The Company’s cash and cash equivalents are deposited in demand accounts primarily at
one
financial institution. Deposits in this institution
may,
from time to time, exceed the federally insured amounts.
 
Concentration of Credit Risk and Other Risks and Uncertainties
 
To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be
no
assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows.
 
Most of the Company’s products to date require clearance or approvals from the FDA or other international regulatory agencies prior to commencing commercial sales. There can be
no
assurance that the Company’s products will receive any of these required clearances or approvals or for the indications requested. If the Company was denied such clearances or approvals or if such clearances or approvals were delayed, it would have a material adverse effect on the Company’s financial results, financial position and future cash flows.
 
The Company is subject to risks common to companies in the medical device industry including, but
not
limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products.
 
The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of
three
main components: a RF, or radio frequency, generator housed in a table-top console, a reusable handpiece and a single-use treatment tip. Included with the system are single-use accessories (e.g. RF return pad, coupling fluid), as well as a cryogen canister that can be used for approximately
four
to
five
procedures, and a foot pedal. The Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other components and materials that comprise the device are currently manufactured by a single supplier or a limited number of suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these
third
-party suppliers would adversely impact the production of our products for a substantial period of time, which could have a material adverse effect on our business, financial condition, operating results and cash flows.
 
In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended
December 31, 
2018,
one
distributor accounted for
21%
of the Company’s revenue. During the year ended
December 31, 2017,
two
distributors together accounted for
35%
of the Company’s revenue.
 
There are
no
direct sales to customers that accounted for more than
10%
of the Company’s revenue during the years ended
December 31, 2018
and
2017.
 
As of
December 31, 2018,
three
distributors, collectively, accounted for
54%
of total accounts receivable, net. As of
December 31, 2017,
two
distributors, collectively, accounted for
57%
of total accounts receivable, net.
  
Accounts Receivable and Allowance for Doubtful Accounts
 
Accounts receivable are recorded at the invoiced amount and are
not
interest bearing. Our typical payment terms vary by region and type of customer (distributor or physician). Occasionally, payment terms of up to
six
months
may
be granted to customers with an established history of collections without concessions. Should we grant payment terms greater than
six
months or terms that are
not
in accordance with established history for similar arrangements, revenue would be recognized as payments become due and payable assuming all other criteria for revenue recognition have been met. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. The allowance for doubtful accounts was
$284,000
and
$221,000
as of
December 31, 2018
and
2017,
respectively.
 
Inventory
 
Inventory is stated at the lower of cost or net realizable value. Inventory as of
December 31, 2018
consisted of
$3,232,000
of finished goods and
$887,000
of raw materials. Inventory as of
December 31, 2017
consisted of
$1,990,000
of finished goods and
$40,000
of raw materials. Cost is determined on an actual cost basis on a
first
-in,
first
-out method. Lower of cost or net realizable value is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory. Excess and obsolete inventory is charged to cost of revenue and a new lower-cost basis for that inventory is established and subsequent changes in facts and circumstances do
not
result in the restoration or increase in that newly established cost basis.
 
As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of
five
years. The amortization of the demos is charged to selling, general and administrative expense and the demos are included in the medical equipment line within the property and equipment, net balance on the consolidated balance sheets as of
December 31, 2018
and
2017.
  
Property and Equipment, net
 
Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of
three
to
seven
years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful lives or the life of the lease. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
 
Impairment of Long-Lived Assets
 
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might
not
be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has
not
identified any such impairment losses to date.
 
Revenue Recognition
 
Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following
five
steps: (
1
) identify the contract with a customer, (
2
) identify the performance obligations in the contract, (
3
) determine the transaction price, (
4
) allocate the transaction price to the performance obligations in the contract, and (
5
) recognize revenue when a performance obligation is satisfied. The Company considers customer purchase orders to be the contracts with a customer. Revenues, net of expected discounts, are recognized when the performance obligations of the contract with the customer are satisfied and when control of the promised goods are transferred to the customer, typically when products, which have been determined to be the only distinct performance obligations, are shipped to the customer. Expected costs of assurance warranties and claims are recognized as expense. Revenue is recognized net of any sales taxes from the sale of the products.
 
Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners.
 
The Company does 
not
 provide its customers with a right of return.
 
Customer Advance Payments
 
From time to time, customers will pay for a portion of the products ordered in advance.  Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities.  The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. 
 
Contract Assets and Liabilities
 
The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities.
No
such assets existed as of 
December 31, 2018
or
2017.
The Company had customer contract liabilities in the amount of
$686,000,
primarily related to marketing programs that performance had
not
yet been delivered to its customers as of
December
31,2018.
No
such contract liabilities existed as of
December 31, 2017.
Separately, accounts receivable, net represents receivables from contracts with customers.
 
Significant Financing Component
 
The Company applies the practical expedient to
not
make any adjustment for a significant financing component if, at contract inception, the Company does
not
expect the period between customer payment and transfer of control of the promised goods or services to the customer to exceed
one
year. During the year ended
December 31, 2018,
the Company did
not
have any contracts for the sale of its products with its customers with a significant financing component.
 
Contract Costs
 
 
The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is
one
year or less. During the year ended
December 31, 2018,
the Company expensed the incremental costs of obtaining the contract as an expense when incurred as the amortization period was
one
 year or less.
 
Shipping and Handling
 
Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. 
 
In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the year ended
December 31, 2018
and consolidated balance sheet as of
December 31, 2018
was as follows (in thousands): 
 
   
For the year ended December 31, 2018
   
   
As Reported
   
Balances
Without
Adoption of
ASC 606
   
Effect of Change
Higher/(Lower)
   
Consolidated Statement of Operations
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
  $
18,517
    $
17,780
    $
737
 
(1)
 
Cost of revenue
  $
11,197
    $
11,209
    $
(12
)
(2)
 
Gross profit
  $
7,320
    $
6,571
    $
749
 
(3)
 
Loss from operations
  $
(44,965
)   $
(45,714
)   $
749
 
(3)
 
Comprehensive and net loss
  $
(49,981
)   $
(50,730
)   $
749
 
(3)
 
Net loss per share:
                         
Basic and diluted
  $
(1.61
)   $
(1.63
)   $
0.02
 
 
                           
Weighted average shares
   
31,059,483
     
31,059,483
     
 
 
 
 
 
(
1
)
  
Change relates to revenue from extended assurance warranties for which
no
deferral is required on the adoption of ASC
606.
 
(
2
)
  
Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC
606.
 
(
3
)
  
Change relates to the net gain adjustment on the adoption of ASC
606.
 
   
As of December 31, 2018
   
   
As Reported
   
Balances
Without
Adoption of
ASC 606
   
Effect of Change
Higher/(Lower)
   
Consolidated Balance Sheets
 
 
 
 
 
 
 
 
 
 
 
 
 
                           
Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued liabilities
  $
6,766
    $
7,014
    $
(248
)
(1)
  
Other noncurrent liabilities
  $
634
    $
1,313
    $
(679
)
(2)
 
                           
Equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Accumulated deficit
  $
(155,385
)   $
(156,311
)   $
926
 
(3)
 
 
 
(
1
)
 
Change relates to the current portion of deferred revenue in connection with the extended warranties
not
required to be recorded under ASC
606,
partially offset by future costs associated with extended warranties required to be recorded on the adoption of ASC
606.
 
(
2
)
 
Change relates to noncurrent portion of deferred revenue in connection with the extended warranties
not
required to be recorded under ASC
606.
 
(
3
)
 
Change relates to
$177,000
cumulative effect adjustment on the adoption of ASC
606
and the net gain adjustment of
$749,000
for the year ended
December 31, 2018.
 
Revenue by Geographic Area:
 
 
Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts).
 
   
Year Ended
 
   
December 31,
 
   
2018
   
2017
 
                 
United States
  $
13,606
     
11,004
 
Asia Pacific
   
2,891
     
3,178
 
Europe and Middle East
   
1,369
     
667
 
Canada
   
563
     
79
 
Latin America
   
51
     
360
 
Other
   
37
     
-
 
Total
  $
18,517
    $
15,288
 
 
The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
 
Investments in Unconsolidated Affiliates
 
The Company uses the equity method to account for its investments in entities that it does
not
control but have the ability to exercise significant influence over the investee. Equity method investments are recorded at original cost and adjusted periodically to recognize (
1
) the proportionate share of the investees’ net income or losses after the date of investment, (
2
) additional contributions made and dividends or distributions received, and (
3
) impairment losses resulting from adjustments to net realizable value. The Company eliminates all intercompany transactions in accounting for equity method investments. The Company records the proportionate share of the investees’ net income or losses in equity in earnings of unconsolidated affiliates on the consolidated statements of operations. The Company utilizes a
three
-month lag in reporting equity income from its investments, adjusted for known amounts and events, when the investee’s financial information is
not
available timely or when the investee’s reporting period differs from our reporting period.
 
The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment
may
not
be recoverable. During the years ended
December 31, 2018
and
2017,
no
impairment charges have been recorded.
 
Product Warranty
 
The Company’s products are generally subject to warranties between
one
and
three
years, which provides for the repair, rework or replacement of products (at the Company’s option) that fail to perform within stated specifications. The Company has assessed the historical claims and, to date, product warranty claims have
not
been significant.
 
 
Advertising Costs
 
Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended
December 31, 2018
and
2017.
  
Research and Development
 
Research and development costs are charged to operations as incurred. Research and development costs include, but are
not
limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.
 
Income Taxes
 
The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than
not
that a tax benefit will
not
be realized.
 
The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is
not
likely, the Company establishes a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against the net deferred tax assets. The Company recorded a full valuation allowance as of
December 31, 2018
and
2017.
Based on the available evidence, the Company believes it is more likely than
not
that it will
not
be able to utilize its deferred tax assets in the future. The Company intends to maintain valuation allowances until sufficient evidence exists to support the reversal of such valuation allowances. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans. Should the actual amounts differ from the Company’s estimates, the carrying value of the Company’s deferred tax assets could be materially impacted.
 
The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than
not
of being sustained on audit, based on the technical merits of the position. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does
not
believe there are any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within
12
months of the reporting date.
 
Accounting for Stock-Based Compensation
 
Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award.
 
The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock.
 
Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
 
Comprehensive Loss
 
Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss
may
include certain changes in equity that are excluded from net loss. For the years ended
December 31, 2018
and
2017,
the Company’s comprehensive loss is the same as its net loss.  
 
Net Loss per Share
 
The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are
not
assumed to have been issued if their effect is anti-dilutive.
 
The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. 
 
   
Year Ended
 
   
December 31,
 
   
2018
   
2017
 
                 
Stock options to purchase common stock
   
4,014,475
     
2,694,224
 
Warrants to purchase common stock
   
642,622
     
642,622
 
Restricted common stock awards
   
57,500
     
10,000
 
 
Recently Issued and Adopted Accounting Standards
 
In
February 2016,
the FASB issued ASU
No.
2016
-
02,
Leases (Topic
842
), which requires an entity that is a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases. This guidance also requires disclosures about the amount, timing, and uncertainty of cash flows arising from leases. This guidance is effective for annual reporting periods beginning after
December 15, 2018,
and interim periods within those annual periods and early adoption is permitted. In
July 2018,
the FASB issued updated guidance which allows an additional transition method to adopt the new leases standard at the adoption date, as compared to the beginning of the earliest period presented, and allows entities to recognize a cumulative-effect adjustment to the beginning balance of retained earnings in the period of adoption. The Company expects to elect to use this transition method at the adoption date of
January 1, 2019,
and, as a result, will record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than
12
months. The Company also plans to elect the practical expedient to
not
separate lease and non-lease components and to use the package of practical expedients upon transition that will retain the lease classification and initial direct costs for any leases that exist prior to adoption of the new guidance.
 
In
August 2016,
the FASB issued ASU
No.
2016
-
15,
“Statement of Cash Flows, Classification of Certain Cash Receipts and Cash Payments (Topic
230
)”. This guidance addresses specific cash flow issues with the objective of reducing the diversity in practice for the treatment of these issues. The areas identified include: debt prepayment or debt extinguishment costs; settlement of
zero
-coupon debt instruments; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies; distributions received from equity method investees; beneficial interests in securitization transactions and application of the predominance principle with respect to separately identifiable cash flows. This guidance is effective for annual reporting periods beginning after
December 15, 2017,
including interim periods within that reporting period, with early adoption permitted. We adopted this guidance as of
January 1, 2018
and the adoption of the guidance did
not
have a significant impact on the condensed consolidated financial statements.
 
In
August 2016,
the FASB issued ASU
No.
2016
-
18,
“Statement of Cash Flows, Restricted Cash (Topic
230
)”. This guidance requires that a statement of cash flows explain the total change during the period of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Amounts described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning of period and end of period to total amounts shown on the statement of cash flows. This guidance is effective for annual reporting periods beginning after
December 15, 2017,
including interim periods within that reporting period, with early adoption permitted. We adopted this guidance as of
January 1, 2018
and the adoption of the guidance did
not
have a significant impact on the condensed consolidated financial statements.
 
In
May 2017,
the FASB issued ASU
No.
2017
-
09,
“Compensation - Stock Compensation (Topic
718
), Scope of Modification Accounting”. This pronouncement provides guidance about which changes to the terms or conditions of a share-based payment award
may
require an entity to apply modification accounting under Topic
718.
This guidance is effective for annual reporting periods beginning after
December 15, 2017,
including interim periods within that reporting period, with early adoption permitted. We adopted this guidance as of
January 1, 2018
and the adoption of the guidance did
not
have a significant impact on the condensed consolidated financial statements.
 
In
June 2018,
the FASB issued ASU
2018
-
07,
“Stock Compensation (Topic
718
) – Improvements to Nonemployee Share- Based Payment Accounting”. The intent of this guidance is to simplify the accounting for nonemployee share-based payment accounting. The amendments in this guidance expand the scope of Topic
718
to include share-based payment transactions for acquiring goods and services from nonemployees. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic
718
are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity- classified nonemployee share-based payment awards are measured at the grant date. Consistent with the accounting for employee share-based payment awards, an entity considers the probability of satisfying performance conditions when nonemployee share-based payment awards contain such conditions. This guidance is effective for annual reporting periods beginning after
December 15, 2018,
including interim periods within the reporting period. We do
not
expect the adoption of this guidance to have a significant effect on our consolidated financial statements.
 
We have reviewed other recent accounting pronouncements and concluded they are either
not
applicable to the business, or
no
material effect is expected on the consolidated financial statements as a result of future adoption.